LentiArray™ CRISPR Positive Control Lentivirus, human HPRT, with GFP
LentiArray™ CRISPR Positive Control Lentivirus, human HPRT, with GFP
Citações e referências (1)
Invitrogen™

LentiArray™ CRISPR Positive Control Lentivirus, human HPRT, with GFP

Optimizing delivery conditions is a critical step in any experiment utilizing the CRISPR/Cas9 system. The Invitrogen™ LentiArray CRISPR Positive ControlLeia mais
Have Questions?
Alterar visualizaçãobuttonViewtableView
Número do catálogoQuantity
A32060100 μL
A328301 mL
Número do catálogo A32060
Preço (BRL)
-
Quantity:
100 μL

Optimizing delivery conditions is a critical step in any experiment utilizing the CRISPR/Cas9 system. The Invitrogen™ LentiArray CRISPR Positive Control Lentivirus gRNA against HPRT is a highly efficient gRNA validated in multiple human cell lines that has achieved editing efficiencies of greater than 80%. It can be used to rapidly determine ideal delivery conditions in order to achieve maximum editing efficiency in your cell model of choice. This construct also expresses emGFP to provide a visual readout of successful transduction that can be used in determining Multiplicity of Infection (MOI).

For Research Use Only. Not for use in diagnostic procedures.
Especificações
Delivery TypeLentiviral
For Use With (Application)Genome Editing
Product LineLentiArray
Product TypegRNA
PromoterU6
Quantity100 μL
Shipping ConditionDry Ice
Control TypePositive Control
FormatTube
RNAi TypegRNA
SpeciesHuman
Unit SizeEach
Conteúdo e armazenamento
1 x 100 μL. Store (at -68°C to -85°C.)

Citações e referências (1)

Citações e referências
Abstract
A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Authors:Sredni ST, Suzuki M, Yang JP, Topczewski J, Bailey AW, Gokirmak T, Gross JN, de Andrade A, Kondo A, Piper DR, Tomita T
Journal:Pediatr Blood Cancer
PubMed ID:28398638
Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to available therapies, more effective and less toxic treatments are needed. We hypothesized that a systematic screening of the kinome will reveal kinases that drive rhabdoid tumors and can be targeted by specific ... More